CGEN - Compugen Ltd.
| Previous Close | 4.0400 |
| Open | 4.0800 |
| Bid | 3.9100 x 1200 |
| Ask | 3.9600 x 1400 |
| Day's Range | 4.0000 - 4.0900 |
| 52 Week Range | 2.0000 - 4.3100 |
| Volume | 158,684 |
| Avg. Volume | 219,107 |
| Market Cap | 241.598M |
| Beta (3Y Monthly) | 2.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4530 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.50 |
- Zacks
MyoKardia Begins Dosing in Phase I Study on Heart Candidate
MyoKardia (MYOK) doses the first patient in phase I study on MYK-224, which is being evaluated for treating patients with hypertrophic cardiomyopathy, a common heart disease.
- Zacks
Vaccinex (VCNX) Attains Full Enrollment in Lung Cancer Study
Vaccinex (VCNX) completes enrollment in a phase Ib/II study of its pipeline candidate pepinemab in combination with Bavencio for treating advanced non-small cell lung cancer.
- Zacks
Mallinckrodt Enrolls First Patient in Liver Disease Study
Mallinckrodt (MNK) recruits the first patient in a mid-stage study on MNK-6106 for the treatment of hepatic cirrhosis and hepatic encephalopathy.
- Zacks
AMAG Q2 Loss Widens, Sales Lag Estimates, 2019 Guidance Cut
AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.
Motley FoolCompugen Ltd. (CGEN) Q2 2019 Earnings Call Transcript
CGEN earnings call for the period ending June 30, 2019.
- PR Newswire
Compugen Reports Second Quarter 2019 Results
HOLON, Israel , Aug. 5, 2019 /PRNewswire/ -- Compugen Ltd. ( Nasdaq: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial ...
- PR Newswire
Compugen Second Quarter 2019 Conference Call Scheduled for Monday, August 5, 2019 at 8:30 AM ET
HOLON, ISRAEL , July 22, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that ...
- PR Newswire
Compugen Expands Intellectual Property Portfolio for COM701 with New U.S. Patent Covering Combination Use with anti-PD-1 Antibody
Previously granted U.S. Patent protects combination of COM701 and COM902 HOLON, Israel , July 16, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader ...
- PR Newswire
Compugen Appoints Eran Perry to Its Board of Directors
HOLON, Israel, July 2, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced the appointment of Mr. Eran Perry to its board of directors, effective July 1, 2019. In addition, the Company announced that Yair Aharonowitz, Ph.D. and Arie Ovadia, Ph.D. will retire from its board of directors and will not be brought for re-election at the next annual general meeting. "Eran is an accomplished business leader with over 20 years of experience in the healthcare industry as well as general management, strategy and finance.
- Simply Wall St.
How Many Compugen Ltd. (NASDAQ:CGEN) Shares Do Institutions Own?
A look at the shareholders of Compugen Ltd. (NASDAQ:CGEN) can tell us which group is most powerful. Large companies...
- Simply Wall St.
Do Institutions Own Shares In Compugen Ltd. (NASDAQ:CGEN)?
If you want to know who really controls Compugen Ltd. (NASDAQ:CGEN), then you'll have to look at the makeup of its...
- Zacks
Compugen (CGEN) Upgraded to Strong Buy: Here's What You Should Know
Compugen (CGEN) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Simply Wall St.
The Compugen (NASDAQ:CGEN) Share Price Is Down 63% So Some Shareholders Are Wishing They Sold
It's nice to see the Compugen Ltd. (NASDAQ:CGEN) share price up 18% in a week. But don't envy holders -- looking back...
- PR Newswire
Compugen Presents Update on COM701 Phase 1 Trial at the 2019 ASCO Annual Meeting
HOLON, Israel, June 3, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress poster at the 2019 ASCO Annual Meeting in Chicago, IL. In a poster (Abstract #TPS2657), titled "A phase I study evaluating COM701 in patients with advanced solid tumors," the Company reported that the sixth patient dose cohort of COM701 monotherapy has been completed and that no dose-limiting toxicities were observed in this and prior dose cohorts. The poster is available on Compugen's website at www.cgen.com.
- Zacks
Compugen (CGEN) Upgraded to Buy: Here's What You Should Know
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- PR Newswire
Compugen to Present at the Jefferies 2019 Healthcare Conference
HOLON, Israel , May 22, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that ...
- Motley Fool
Compugen Ltd. (CGEN) Q1 2019 Earnings Call Transcript
CGEN earnings call for the period ending March 31, 2019.
- Associated Press
Compugen: 1Q Earnings Snapshot
On a per-share basis, the Holon, Israel-based company said it had a loss of 14 cents. The company's shares closed at $3.46. A year ago, they were trading at $3.25. _____ This story was generated by Automated ...
- PR Newswire
Compugen Reports First Quarter 2019 Results
HOLON, Israel , May 20, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial ...
- PR Newswire
Compugen Doses First Patient in COM701/Opdivo® (Nivolumab) Combination Arm of Phase 1 Study in Patients With Advanced Solid Tumors
HOLON, Israel, May 20, 2019 /PRNewswire/ -- Compugen Ltd. (CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that it has dosed the first patient in the combination arm of its Phase 1 study, combining escalating doses of COM701 with a fixed dose of Opdivo® (nivolumab) in patients with advanced solid tumors. "Our successful progression through the COM701 monotherapy dose escalation arm, enabled us to initiate the combination study with COM701 and Opdivo," stated Anat Cohen-Dayag, Ph.D., President and CEO of Compugen.
- PR Newswire
Compugen First Quarter 2019 Conference Call Scheduled for Monday, May 20, 2019 at 8:30 AM ET
HOLON, Israel , May 6, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that ...
- Zacks
What Makes Compugen (CGEN) a New Strong Buy Stock
Compugen (CGEN) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- PR Newswire
Compugen Presents Update on COM701 Phase 1 Trial at the 2019 AACR Annual Meeting
HOLON, Israel, April 3, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its ongoing Phase 1 clinical trial evaluating COM701, a first-in-class therapeutic antibody targeting PVRIG, was featured in a trial-in-progress poster at The 2019 AACR Annual Meeting in Atlanta, GA. In a poster titled "Phase I study of COM701 (a novel checkpoint inhibitor of PVRIG) in patients with advanced solid tumors", the Company reported that the fifth dose level patient cohort of COM701 monotherapy has been completed and that no dose-limiting toxicities were reported. The poster presented at the meeting is available on Compugen's website.
- PR Newswire
Chinese Regulatory Authority Approves IND Application of Oramed's Oral Insulin Capsules
NEW YORK, March 26, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (ORMP) (ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that its Chinese partner, Hefei Tianhui Incubator of Technologies Co., Ltd. ("HTIT"), has reached the significant regulatory milestone of approval of an investigational new drug application ("IND") for two doses of its oral insulin (ORMD-0801). The approval of the IND by the Center For Drug Evaluation of the China National Medical Products Administration ("NMPA", formerly the CFDA) of the oral insulin paves the way for the start of clinical trials in China. "We are pleased that the Chinese regulatory authorities have approved the IND, as it sets a clear path forward for approval of oral insulin in China, bringing oral insulin closer to becoming a reality in the Chinese market," stated Oramed CEO Nadav Kidron.
